Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual Meeting

Stock Information for Profound Medical Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Profound Medical Corp.

Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference
Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results
Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology's Kidney Week 2025 Annual Meeting
Eledon Pharmaceuticals to Present at Guggenheim Second Annual Healthcare Innovation Conference
Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.